BNP/CALL/MODERNA/100/0.1/19.12.25 Stock

DE000PC1G815

Market Closed - Bid/Ask 02:20:43 2024-07-09 am EDT			Pre-market 02:35:51 am
3.98 ^EUR	+0.76%		4.015	+0.88%

Current month	-4.82%
1 month	-40.60%

Comparison chart between the derivative product and it's underlying value

End-of-day quotes

Chart MODERNA, INC.

Latest news about MODERNA, INC.

Moderna and Mitsubishi Tanabe Pharma Corporation Enter Joint Agreement to Promote Moderna?s Mrna Respiratory Vaccine Portfolio in Japan, Including Covid-19 Vaccines	07:00pm	CI
HilleVax to discontinue development of norovirus vaccine for infants; shares plummet	Jul. 08	RE
Study finds Pfizer's RSV vaccine not tied to higher risk of pre-term births	Jul. 08	RE
The US will pay Moderna $176 million to develop an mRNA pandemic flu vaccine	Jul. 02	AQ

More news

Quotes 5-day view

Date	Price	Change
24-07-09	3.98	+0.76%
24-07-08	3.95	-3.42%
24-07-05	4.09	-0.73%
24-07-04	4.12	+4.83%
24-07-03	3.93	-2.48%

Real-time Boerse Frankfurt Warrants

Last update July 09, 2024 at 02:20 am EDT

More quotes

Static data

Product type	Plain-Vanilla-Warrants
Buy / Sell	CALL
Underlying	MODERNA, INC.
Issuer	BNP Paribas
WKN	PC1G81
ISIN	DE000PC1G815
Date issued	2023-12-08
Strike	100 $
Maturity	2025-12-19 (529 Days)
Parity	10 : 1
Emission price	1.81 €
Emission volume	N/A
Settlement	cash
Currency	EUR

Technical Indicators

Highest since issue	8.11 €
Lowest since issue	1.79 €
Spread	0.02 €
Spread %	0.50%

Company Profile

Moderna, Inc. is a biotechnology company specialized in research and development of therapeutics and vaccines for cancer, infectious, autoimmune and cardiovascular diseases. Net sales break down by type of revenue as follows: - revenue from product sales (95.7%) ; - revenues from grants (4%); - revenues from collaboration agreements (0.3%). At the end of 2021, the group possessed a portfolio of 15 products in clinical development, of which 3 in phase III, 8 in phase II and 4 in phase I, and 12 products in preclinical development. Net sales are distributed geographically as follows: the United States (33.4%), Europe (37.1%) and other (29.5%).

Sector

More about the company